GHRL and cancer: Promising drugs include ghrelin secretagogues, such as anamorelin, which significantly stimulate appetite in patients with cancer; however, in patients aged ≥65 years, the effects of these drugs are less significant, and their use does not lead to improved handgrip strength or decreased mortality and/or disability [37,38].